Egypt’s EDA elected vice chair of African ML3 alliance

The Egyptian Drug Authority (EDA) has been elected Vice Chair of the Steering Committee of the Alliance of National Regulatory Authorities (NRAs) in Africa classified as WHO-Listed ML3 (Maturity Level 3), the Cabinet said.

This achievement underscores African confidence in Egypt’s regulatory capabilities and highlights the EDA’s leading role in shaping a unified pharmaceutical oversight framework across the continent.

The alliance serves as a vital coordination platform for African regulators with WHO Level 3 classification, aiming to align policies and regulatory efforts to ensure the availability of safe, effective, and high-quality medicines throughout Africa.

Ali El-Ghamrawy, EDA’s head, highlighted the authority’s international standing, regulatory expertise, governance, and efforts in continental integration in drug regulation, registration, and manufacturing.

He added that the appointment reinforces Egypt’s vision of enhancing health security in Africa and advancing sustainable development goals through flexible and efficient regulatory policies that support a self-reliant pharmaceutical industry across the continent.

This appointment is part of the EDA’s ongoing efforts to cement its role as a regional reference authority and to promote coordinated health systems through regulatory excellence and technical cooperation.

Attribution: Amwal Al Ghad English
Subediting: M. S. Salama